SecBot SecBot
PRESS-RELEASE ·Filed Jun 14, 2026

CLDX

Celldex Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The clean safety profile and novel mechanism validation are significant for Celldex's mast cell franchise. Watch for initiation of Phase 1b asthma data and subsequent proof-of-concept readouts in allergic rhinitis/food allergy, which could further de-risk the platform.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$32.12
T+0 close · Jun 14, 2026 · via day close
Latest settled
+18.62%
T+60 · $38.10
Vs SPY
+18.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $32.12entry
  2. T+1 · 5mo ago +0.62%α +1.22% · $32.32
  3. T+5 · 5mo ago +4.02%α +5.40% · $33.41
  4. T+20 · 4mo ago +19.96%α +20.71% · $38.53
  5. T+60 · 2mo ago +18.62%α +18.22% · $38.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug showed rapid, durable, dose-dependent reductions in serum tryptase (indicating mast cell depletion) and was well-tolerated at all doses with no dose-limiting toxicities or related serious adverse events. This validates a novel mechanism (neutralizing soluble SCF to selectively inhibit KIT signaling in mast cells) and supports advancing into Phase 1b proof-of-concept studies in asthma, allergic rhinitis, and food allergy.

Key Facts

  • CDX-622 induced rapid, profound, dose-dependent, and durable reductions in serum tryptase, indicating tissue mast cell depletion.
  • No dose-limiting toxicities or related serious adverse events; most common adverse event was Grade 1 headache.
  • No changes in hair/skin pigmentation or meaningful impact on hematologic parameters, addressing a key safety concern for KIT-targeting therapies.
  • CDX-622 exhibited monoclonal antibody-like pharmacokinetics with extended half-life and good subcutaneous bioavailability.
  • Phase 1b proof-of-mechanism study in mild to moderate asthma is ongoing; additional proof-of-concept studies in allergic rhinitis and food allergy are planned.
  • Celldex also presented non-human primate data showing targeting soluble SCF depletes mast cells without affecting spermatogenesis or melanogenesis.
  • CDX-622 builds on Celldex's barzolvolimab platform, which is in Phase 3 for chronic urticaria and Phase 2 for prurigo nodularis and atopic dermatitis.

Financial Impact

No financial data provided; clinical-stage biotech with no approved products or revenue. Positive Phase 1 data de-risks the CDX-622 program and expands Celldex's pipeline optionality in inflammatory diseases.

pipeline valueclinical development risk

Risk Factors

  • CDX-622 is still in early-stage development (Phase 1b); clinical failure in later-stage trials remains a risk.
  • Competition from other mast cell-targeting therapies (e.g., barzolvolimab, other anti-SCF/TSLP agents) could limit commercial potential.
  • No financial data or guidance provided; the company's cash runway and ability to fund multiple Phase 2 programs is not disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311438

Track record

21 reports on CLDX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +12.43% at T+60 after the Mar 27, 2026 report. 3 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
  2. Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  7. Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  8. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  9. Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
  10. Jun 14, 202622w ago Press Release Bullish 7/10 Viewing Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 14, 2026